Dare Bioscience, Inc.
Summary
Dare Bioscience, Inc. filed a Form D on 2026-06-02, raising $65.0M in a private placement backed by Flagship Pioneering and ARCH Venture Partners. The first sale date was 2026-06-01, indicating the capital is already deployed. This is a significant raise for a private company in the Technology Venture sector.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Full Analysis
Executive Summary
Dare Bioscience, Inc. filed a Form D on 2026-06-02, raising $65.0M in a private placement backed by Flagship Pioneering and ARCH Venture Partners. The first sale date was 2026-06-01, indicating the capital is already deployed. This is a significant raise for a private company in the Technology Venture sector.
Investor Edge
Watch for a subsequent Form D/A amendment, which would indicate additional capital or changed terms, signaling strong demand or a pivot in strategy. Also monitor for any public announcements from Dare Bioscience regarding partnerships or regulatory milestones.
Sector capital positioning
This $65M raise signals strong institutional appetite for high-risk, high-reward technology ventures, particularly those with ties to top-tier life science venture firms.
Convergence Signals
No direct public signals are evident from the filing data. However, the involvement of Flagship Pioneering and ARCH Venture Partners suggests potential connections to novel platform technologies or therapeutic assets that may have patent filings or upcoming clinical milestones.
Key Takeaways
- Dare Bioscience raised $65.0M in a private placement with first sale on 2026-06-01.
- Backed by elite venture firms Flagship Pioneering and ARCH Venture Partners.
- No public ticker; this is a private company filing a Regulation D notice.
Risk Indicators & Flags
No red flags in this initial Form D filing. The amount is large but consistent with the backing of top-tier VCs. No D/A amendments yet. Sector is Technology Venture, which is broad; specific risk depends on the company's actual product or service, which is not disclosed in the filing.
Verification & References
Filing is a Form D (initial notice) with SEC accession 000149315226026666. Verified via SEC EDGAR at https://www.sec.gov/cgi-bin/browse-edgar?company=DEFA14A%20-%20Dare%20Bioscience%2C%20Inc.%20(0001401914)%20(Filer)&type=D&action=getcompany. Amount raised is $65.0M. Related persons include Flagship Pioneering and ARCH Venture Partners.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Matthias Therapeutics, LLC
Uniform Bio Inc.
Anika Therapeutics, Inc.
DEF 14A - Outlook Therapeutics, Inc.
Strategy Inc
Outlook Therapeutics, Inc.
Pacira BioSciences, Inc.
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Adjusting Imports of Polysilicon and its Derivatives into the United States
This proclamation invokes Section 232 of the Trade Expansion Act to impose a minimum import price (MIP) program on polysilicon and its derivatives, a 15% ad valorem tariff on polysilicon derivatives, and directs the Secretary of Commerce to offer incentives for domestic production. It aims to protect and revive the U.S. polysilicon industry by restricting imports that threaten national security, particularly for semiconductor and solar supply chains.
Presidential Determination Pursuant to Section 101 of the Defense Production Act of 1950, as Amended, on Recoverable Critical Minerals and Materials
This memorandum invokes the Defense Production Act (DPA) Section 101 to declare that recoverable critical minerals and materials (such as black mass, end-of-life rare-earth magnets, and scrap) are essential to national defense and that the U.S. cannot meet defense needs without disrupting civilian markets. It directs the Secretary of Commerce to issue regulations and take actions—including priority contracts and supply-chain interventions—to rapidly expand domestic recovery and processing of these materials, while explicitly excluding copper scrap already covered by a separate proclamation.
Securing America’s Defense Supply Chains and Ensuring Domestic Acquisition of Critical Materials
This executive order restricts waivers for foreign-sourced critical materials in defense contracts, effective January 1, 2027, and mandates that defense contractors map their supply chains from raw materials to end products, vet subcontractors for risks, and prohibit covered materials from unreliable foreign suppliers. It directs the Secretary of War to enforce strict compliance, including requiring mitigation plans for any non-compliant materials and establishing penalties for fraud or willful noncompliance.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →